Fluoxetine, on the other hand, mitigates cardio-cerebral injury in individuals with myocardial infarction and comorbid depression by suppressing the TNF-α/TNFR/NF-κB pathway in macrophages, while also lowering pro-inflammatory cytokines such as IL - 17 and IFN-γ (89). The gene discussed is NFKB1; the disease is depressive disorder.